{
    "clinical_study": {
        "@rank": "25226", 
        "arm_group": {
            "arm_group_label": "Atrasentan", 
            "arm_group_type": "Experimental", 
            "description": "Atrasentan daily (QD) for 26 weeks"
        }, 
        "brief_summary": {
            "textblock": "This study is being conducted to evaluate the effects of Atrasentan on sperm production and\n      the function of the testicles in male subjects with Type 1 or 2 Diabetes and Nephropathy."
        }, 
        "brief_title": "Atrasentan Spermatogenesis and Testicular Function", 
        "completion_date": {
            "#text": "April 2017", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Nephropathy", 
            "Diabetes"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Kidney Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Males 30 to 75 years of age\n\n          -  Type 1 or 2 diabetes and has been treated with at least one anti-hyperglycemic\n             medication and angiotensin-converting enzyme inhibitors (ACEi)/angiotensin receptor\n             blockers (ARB) (renin-angiotensin system [RAS] inhibitor) for at least 2 months prior\n             to Screening\n\n          -  Estimated Glomerular Filtration Rate (eGFR) equal to or greater than 50 mL/min with\n             the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Formula and Urine\n             Albumin-to-Creatinine Ratio (UACR) equal to or greater than 30 and  less than 5,000\n             mg/g creatinine.\n\n          -  Able to provide a semen specimen at the required intervals.\n\n          -  Baseline sperm concentration \u2265 30 million per mL.\n\n        Exclusion Criteria:\n\n          -  Treatment with hormone suppressive agents or cancer chemotherapy within the past 6\n             months or planned during the study.\n\n          -  History of moderate or severe peripheral edema, pulmonary edema or facial edema\n             unrelated to trauma or  history of myxedema in the prior 6 months to Screening.\n\n          -  History of pulmonary hypertension requiring either oxygen therapy and/or endothelin\n             receptor antagonist or phosphodiesterase therapy or any lung disease requiring oxygen\n             therapy.\n\n          -  Documented diagnosis of heart failure, previous hospitalization for heart failure or\n             current or constellation of symptoms (dyspnea on exertion, pedal edema, orthopnea,\n             paroxysmal nocturnal dyspnea) felt to be compatible with heart failure, that was not\n             explained by other causes, and for which there was a change in medication or other\n             management directed at heart failure.\n\n          -  History of hormone replacement therapy.\n\n          -  Evidence of hypogonadism by clinical exam."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "30 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 14, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02118714", 
            "org_study_id": "M12-919"
        }, 
        "intervention": {
            "arm_group_label": "Atrasentan", 
            "description": "Atrasentan", 
            "intervention_name": "Atrasentan", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Diabetic Nephropathies", 
            "Urologic Diseases", 
            "Diabetes Mellitus", 
            "Endocrine System Diseases", 
            "Kidney Diseases", 
            "Diabetes Complications"
        ], 
        "lastchanged_date": "April 17, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Albany", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "12208"
                    }, 
                    "name": "Site Reference ID/Investigator# 124435"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 124435", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bala Cynwyd", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19004"
                    }, 
                    "name": "Site Reference ID/Investigator# 124277"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 124277", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Single-Country, Multicenter, Single-Arm Study of the Effects of Atrasentan on Spermatogenesis and Testicular Function", 
        "overall_contact": {
            "email": "melissa.wigderson@abbvie.com", 
            "last_name": "Melissa  Wigderson, MD", 
            "phone": "847-393-5607"
        }, 
        "overall_contact_backup": {
            "email": "elysa.noon@abbvie.com", 
            "last_name": "Elysa  Noon, PhD", 
            "phone": "847-937-8311"
        }, 
        "overall_official": {
            "affiliation": "AbbVie", 
            "last_name": "Melissa   Wigderson, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Duplicate semen samples will be collected.", 
            "measure": "Proportion of subjects who have a sperm concentration < 15 million  per mL", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 26 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02118714"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Duplicate semen samples will be collected during the Observational Period. Sperm concentration will be calculated as measure of the number sperm per milliliter of semen.", 
                "measure": "Proportion of subjects who enter the Observation Period and do not return to within 15% of Week 0 by 52 weeks after treatment discontinuation", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 52 weeks"
            }, 
            {
                "description": "Duplicate semen samples will be collected during the Treatment and Observation Periods.", 
                "measure": "Change in sperm motility", 
                "safety_issue": "Yes", 
                "time_frame": "From Week 0 to Week 26 and up to Week 52 after the end of treatment"
            }, 
            {
                "description": "Serum hormones levels will be tested during the Treatment and Observational Periods.", 
                "measure": "Change in serum testosterone", 
                "safety_issue": "Yes", 
                "time_frame": "From Week 0 to Week 26 and up to Week 52 after the end of treatment"
            }, 
            {
                "description": "Serum hormones levels will be tested during the Treatment and Observational Periods.", 
                "measure": "Change in estradiol", 
                "safety_issue": "Yes", 
                "time_frame": "From Week 0 to Week 26 and up to Week 52 after the end of treatment"
            }, 
            {
                "description": "Serum hormones levels will be tested during the Treatment and Observational Periods.", 
                "measure": "Change in Lutenizing Hormone (LH)", 
                "safety_issue": "Yes", 
                "time_frame": "From Week 0 to Week 26 and up to Week 52 after the end of treatment"
            }, 
            {
                "description": "Serum hormones levels will be tested during the Treatment and Observational Periods.", 
                "measure": "Change in Follicle Stimulating Hormone (FSH)", 
                "safety_issue": "Yes", 
                "time_frame": "From Week 0 to Week 26 and up to Week 52 after the end of treatment"
            }, 
            {
                "description": "Serum hormones levels will be tested during the Treatment and Observational Periods.", 
                "measure": "Change in inhibin B", 
                "safety_issue": "Yes", 
                "time_frame": "From Week 0 to Week 26 and up to Week 52 after the end of treatment"
            }, 
            {
                "description": "Duplicate semen samples will be collected during the Treatment and Observational Periods. The percentage of sperm with normal versus abnormal morphology will be determined via microscopic analysis.", 
                "measure": "Change in  sperm morphology", 
                "safety_issue": "Yes", 
                "time_frame": "From Week 0 to Week 26 and up to Week 52 after the end of treatment"
            }, 
            {
                "description": "Duplicate semen samples will be collected during the Treatment and Observation Periods.", 
                "measure": "Change in  semen volume", 
                "safety_issue": "Yes", 
                "time_frame": "From Week 0 to Week 26 and up to Week 52 after the end of treatment"
            }, 
            {
                "description": "Duplicate semen samples will be collected during the Treatment and Observational Periods. Sperm concentration will be calculated as measure of the number sperm per milliliter of semen.", 
                "measure": "Change in sperm concentration", 
                "safety_issue": "Yes", 
                "time_frame": "From Week 0 to Week 26 and up to Week 52 after the end of treatment"
            }
        ], 
        "source": "AbbVie", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AbbVie", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}